

2022 - 2023 Board of Directors

President

David A. Khan, MD, FAAAAI University of Texas Southwestern Medical Center Dallas, TX

President-Elect

Jonathan A. Bernstein, MD, FAAAAI University of Cincinnati College of Medicine Bernstein Allergy Group and Clinical Research Center Cincinnati, OH

Secretary-Treasurer

Paul V. Williams, MD, FAAAAI Northwest Asthma & Allergy Center Seattle, WA

Immediate Past-President

Giselle Mosnaim, MD, MS, FAAAAI NorthShore University HealthSystem Evanston, IL

At-Large Executive Committee Member

Stuart L. Abramson, MD, PhD, AE-C, FAAAAI Shannon Medical Center/Shannon Clinic San Angelo, TX

At-Large Members

Cem Akin, MD, PhD, FAAAAI University of Michigan Ann Arbor, MI

Leonard B. Bacharier, MD, FAAAAI Vanderbilt University Medical Center Nashville, TN

Priya J. Bansal, MD, FAAAAI Asthma and Allergy Wellness Center St. Charles, IL

Carla M. Davis, MD, FAAAAI Baylor College of Medicine Houston, TX

Denise A. DiPrimio-Kalman, DO, FAAAAI Nemours/Al DuPont Hospital for Children Wilmington, DE

Anna H. Nowak-Wegrzyn, MD, PhD, FAAAAI NYU Grossman School of Medicine New York, NY

Tamara T. Perry, MD, FAAAAI UAMS/Arkansas Children's Hospital Little Rock, AR

Wanda Phipatanakul, MD, MS, FAAAAI Boston Children's Hospital | Harvard Medical School Boston, MA

Thanai Pongdee, MD, FAAAAI Mayo Clinic Rochester, MN

Sarbjit (Romi) Saini, MD, FAAAAI Johns Hopkins Allergy Asthma Center Baltimore, MD

Frank Virant, MD, FAAAAI Northwest Asthma & Allergy Center Seattle, WA

Executive Vice President Thomas A. Fleisher, MD, FAAAAI

Executive Director Rebecca Brandt, CAE

Executive Director Emeritus Kay Whalen, MBA, CAE June 14, 2023

The Honorable Joe Manchin III 306 Hart Senate Office Building Washington, D.C. 20510

The Honorable Jeanne Shaheen 506 Hart Senate Office Building Washington, D.C. 20510 The Honorable Joni Ernst 260 Russell Senate Office Building Washington, D.C. 20510

The Honorable Jerry Moran 521 Dirksen Senate Office Building Washington, D.C. 20510

Re: The Protecting Rural Telehealth Access Act (S. 1636)

Dear Senators Manchin, Ernst, Shaheen, and Moran:

I write on behalf of the American Academy of Allergy, Asthma & Immunology (AAAAI) to thank you for your leadership in reintroducing S.1636, the *Protecting Rural Telehealth Access Act*, and to offer the AAAAI's support. We urge Congress to enact this legislation to modernize and expand our healthcare delivery system to continue support for patient access to telehealth services as we transition beyond the pandemic.

Established in 1943, AAAAI is a professional organization with more than 7,000 members in the United States, Canada and 72 other countries. This membership includes board certified allergist/immunologists, other medical specialists, allied health and related healthcare professionals — all with a special interest in the research and treatment of patients with allergic and immunological diseases.

AAAAI's members treat a variety of patients that are at a disproportionally higher risk for serious and potentially life-threatening complications related to COVID-19, including those with compromised immune systems and asthma. AAAAI's members are also uniquely qualified to diagnose and treat seasonal allergies. During the pandemic, the ability for our members to utilize telehealth services to differentiate the symptoms of COVID-19 from seasonal allergies served as a critical tool in both keeping patients from necessary but potentially dangerous visits to their doctor and relieve the bandwidth issues expected at physician offices, urgent care centers, and emergency rooms across the country as the virus continues to spread. Telehealth waivers and

(more)

flexibilities also allowed allergists to increase their reach to more distant and rural communities improving access to care.

Through the Centers for Medicare and Medicaid Services' (CMS) numerous virtual care and telehealth flexibilities offered through rulemakings related to the COVID-19 pandemic, AAAAI members reported increased patient uptake of telehealth and virtual technology platforms that are helping them diagnose, treat, and manage the care of Medicare and Medicaid patients with allergies, asthma, and other respiratory and immunologic diseases. The Academy appreciates Congress' efforts to extend these flexibilities beyond the termination of the COVID-19 public health emergency in May. The AAAAI also supports legislative efforts to make certain telehealth flexibilities permanent.

Given AAAAI members' positive experiences with telehealth, our organization especially appreciates the provisions in the *Protecting Rural Telehealth Access Act* that would provide payment-parity for audio-only health services for clinically appropriate appointments and waive permanently certain geographic restrictions on telehealth services and expand originating sites to include the home and other sites.

Thank you for your leadership in introducing legislation to ensure flexible patient access to care through telehealth services. The AAAAI looks forward to working with you to advance the *Protecting Rural Telehealth Access Act* in the 118th Congress.

As issues related to allergies, asthma, and immunological disorders arise, I encourage you to contact Sheila Heitzig, JD, MNM, CAE, AAAAI Director of Practice and Policy, at (414) 272-6071 or sheitzig@aaaai.org if you have any questions.

Sincerely,

Jonathan A. Bernstein, MD FAAAAI

nathan Simsten

President, American Academy of Allergy, Asthma & Immunology